Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 2 (2005), Issue 3 (March)

1. Photothermal sensitisation: evidence for the lack of oxygen effect on the photosensitising activity.
   Photochem Photobiol Sci, 4(3): 251-3. [Abstract] [Full-text]
2. Healing sound: the use of ultrasound in drug delivery and other therapeutic applications.
   Nat Rev Drug Discov, 4(3): 255-60. [Abstract] [Full-text]
3. Therapeutic applications of polymeric artificial cells.
   Nat Rev Drug Discov, 4(3): 221-35. [Abstract] [Full-text]
4. Precipitation of insulin products used for continuous subcutaneous insulin infusion.
   Diabetes Technol Ther, 7(1): 142-50. [Abstract] [Full-text]
5. Run-to-run control of meal-related insulin dosing.
   Diabetes Technol Ther, 7(1): 48-57. [Abstract] [Full-text]
6. Unintended medication discrepancies at the time of hospital admission.
   Arch Intern Med, 165(4): 424-9. [Abstract] [Full-text]
7. The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy.
   Arch Intern Med, 165(4): 416-23. [Abstract] [Full-text]
8. Antibiotic prophylaxis and non-group B streptococcal neonatal sepsis.
   Obstet Gynecol, 105(3): 581-6. [Abstract] [Full-text]
9. Deferiprone therapy for transfusional iron overload.
   Best Pract Res Clin Haematol, 18(2): 299-317. [Abstract] [Full-text]
10. Perspectives of the management of childhood lymphoma: experience at Tygerberg Hospital, Western Cape, South Africa.
    Transfus Apher Sci, 32(1): 27-31. [Abstract] [Full-text]
11. A randomized, double-blind, placebo-controlled trial to determine effectiveness of antibiotic prophylaxis for tension-free mesh herniorrhaphy.
    J Am Coll Surg, 200(3): 393-7; discussion 397-8. [Abstract] [Full-text]
12. A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
    Eur J Cancer, 41(4): 539-48. [Abstract] [Full-text]
13. Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
    Eur J Cancer, 41(4): 502-7. [Abstract] [Full-text]
14. Microencapsulation peptide and protein drugs delivery system.
    Colloids Surf B Biointerfaces, 41(2): 117-20. [Abstract] [Full-text]
15. Incorporating zosteric acid into silicone coatings to achieve its slow release while reducing fresh water bacterial attachment.
    Colloids Surf B Biointerfaces, 41(2): 83-93. [Abstract] [Full-text]
16. Impact of inadequate surgical antibiotic prophylaxis on perioperative outcome and length of stay on ICU in general and trauma surgery. Analysis using automated data collection.
    Int J Antimicrob Agents, 25(3): 231-6. [Abstract] [Full-text]
17. Risk estimates for drugs suspected of being associated with Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study.
    Intern Med J, 35(3): 188-90. [Abstract] [Full-text]
18. Two-dimensional dose finding in discrete dose space.
    Biometrics, 61(1): 217-22. [Abstract] [Full-text]
19. Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirin.
    Am J Hematol, 78(3): 188-92. [Abstract] [Full-text]
20. Clopidogrel administration prior to coronary artery bypass grafting surgery: the cardiologist's panacea or the surgeon's headache?
    Eur Heart J, 26(6): 576-83. [Abstract] [Full-text]
21. A description of Canadian and United States physician reimbursement for thrombolytic therapy administration in acute ischemic stroke.
    Stroke, 36(3): 682-7. [Abstract] [Full-text]
22. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis.
    Eur Heart J, 26(6): 567-75. [Abstract] [Full-text]
23. Polymorphism of pyridinium amphiphiles for gene delivery: influence of ionic strength, helper lipid content, and plasmid DNA complexation.
    Biophys J, 88(3): 2104-13. [Abstract] [Full-text]
24. Validation of a discharge summary term search method to detect adverse events.
    J Am Med Inform Assoc, 12(2): 200-6. [Abstract] [Full-text]
25. Current prescribing patterns in outpatient child and adolescent psychiatric practice in central New York.
    J Child Adolesc Psychopharmacol, 15(1): 57-61. [Abstract] [Full-text]
26. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer.
    JAMA, 293(9): 1073-81. [Abstract] [Full-text]
27. Hyperfractionated radiation therapy for locoregionally advanced nasopharyngeal cancer.
    Jpn J Clin Oncol, 35(3): 116-20. [Abstract] [Full-text]
28. Sample preparation optimization for assay of active pharmaceutical ingredients in a transdermal drug delivery system using experimental designs.
    J Pharm Biomed Anal, 37(3): 493-8. [Abstract] [Full-text]
29. A mathematical model of combination therapy using the EGFR signaling network.
    Biosystems, 80(1): 57-69. [Abstract] [Full-text]
30. The relationship between fatigue and quality of life and inflammation during anthracycline-based chemotherapy in breast cancer.
    Biol Psychol, 69(1): 85-96. [Abstract] [Full-text]
31. Influence of hormone therapy on the cardiovascular responses to stress of postmenopausal women.
    Biol Psychol, 69(1): 39-56. [Abstract] [Full-text]
32. Use of hand held photopolymerizer to photoinactivate Streptococcus mutans.
    Arch Oral Biol, 50(3): 353-9. [Abstract] [Full-text]
33. Pilot study to assess patient outcomes following endoscopic application of photodynamic therapy for advanced cholangiocarcinoma.
    J Gastroenterol Hepatol, 20(3): 415-20. [Abstract] [Full-text]
34. Poly(2-hydroxyethyl methacrylate) wound dressing containing ciprofloxacin and its drug release studies.
    J Mater Sci Mater Med, 16(2): 95-100. [Abstract] [Full-text]
35. Evaluation of TS-1 based treatment and expression of thymidylate synthase and dihydropyrimidine dehydrogenase on oral squamous cell carcinoma.
    Oral Oncol, 41(3): 276-82. [Abstract] [Full-text]
36. Antifungal effect of 5-aminolevulinic acid PDT in Trichophyton rubrum.
    Mycoses, 48(2): 101-7. [Abstract] [Full-text]
37. Novel site-specific systemic delivery of Rapamycin with perfluorobutane gas microbubble carrier reduced neointimal formation in a porcine coronary restenosis model.
    Catheter Cardiovasc Interv, 64(3): 389-94. [Abstract] [Full-text]
38. Microemulsions as colloidal vehicle systems for dermal drug delivery. Part V: Microemulsions without and with glycolipid as penetration enhancer.
    J Pharm Sci, 94(4): 821-7. [Abstract] [Full-text]
39. Influence of asymmetric donor-receiver ion concentration upon transscleral iontophoretic transport.
    J Pharm Sci, 94(4): 847-60. [Abstract] [Full-text]
40. Comparison of three anesthetic techniques for off-pump coronary artery bypass grafting: general anesthesia, combined general and high thoracic epidural anesthesia, or high thoracic epidural anesthesia alone.
    J Cardiothorac Vasc Anesth, 19(1): 32-9. [Abstract] [Full-text]
41. Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
    J Infect Dis, 191(7): 1164-8. [Abstract] [Full-text]
42. Rescue use of endovascular snare for acute basilar artery embolic occlusion resistant to balloon angioplasty and fibrinolysis therapy.
    Minim Invasive Neurosurg, 48(1): 53-6. [Abstract] [Full-text]
43. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
    Clin Cancer Res, 11(4): 1534-8. [Abstract] [Full-text]
44. Phase I trial of combretastatin a-4 phosphate with carboplatin.
    Clin Cancer Res, 11(4): 1527-33. [Abstract] [Full-text]
45. Endocrine effects of tamoxifen plus exemestane in postmenopausal women with breast cancer.
    Clin Cancer Res, 11(4): 1500-3. [Abstract] [Full-text]
46. Immune reconstitution inflammatory syndrome (IRIS)--another new disease entity following treatment initiation of HIV infection.
    Infection, 33(1): 43-5. [Abstract] [Full-text]
47. The impact of private and public health insurance on medication use for adults with chronic diseases.
    Med Care Res Rev, 62(2): 231-49. [Abstract] [Full-text]
48. Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis.
    Fertil Steril, 83(3): 558-66. [Abstract] [Full-text]
49. Medication safety issues in the emergency department.
    Crit Care Nurs Clin North Am, 17(1): 65-9, xi. [Abstract] [Full-text]
50. Short antibiotic prophylaxis for bacterial infections in a neonatal intensive care unit: a randomized controlled trial.
    J Hosp Infect, 59(4): 292-8. [Abstract] [Full-text]
51. Applications of liposomes in ophthalmology.
    Surv Ophthalmol, 50(2): 167-82. [Abstract] [Full-text]
52. Mammalian carboxylesterases: from drug targets to protein therapeutics.
    Drug Discov Today, 10(5): 313-25. [Abstract] [Full-text]
53. Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases.
    Reprod Toxicol, 19(4): 557-61. [Abstract] [Full-text]
54. By what mechanism do leeches help to salvage ischaemic tissues? A review.
    Br J Oral Maxillofac Surg, 43(2): 155-60. [Abstract] [Full-text]
55. Rescue percutaneous coronary intervention for failed thrombolysis in a patient with anomalous coronary arteries.
    Int J Cardiol, 99(2): 325-6. [Abstract] [Full-text]
56. Properties of various phospholipid mixtures as emulsifiers or dispersing agents in nanoparticle drug carrier preparations.
    Colloids Surf B Biointerfaces, 41(4): 257-62. [Abstract] [Full-text]
57. A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery.
    Biomol Eng, 21(6): 145-55. [Abstract] [Full-text]
58. A pharmacist model of perceived responsibility for drug therapy outcomes.
    Soc Sci Med, 60(10): 2393-403. [Abstract] [Full-text]
59. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release.
    Prog Lipid Res, 44(1): 68-97. [Abstract] [Full-text]
60. Lipid based particulate formulations for the delivery of antigen.
    Immunol Cell Biol, 83(2): 97-105. [Abstract] [Full-text]
61. Treatment of peritoneal dissemination from gastric cancer by peritonectomy and chemohyperthermic peritoneal perfusion.
    Br J Surg, 92(3): 370-5. [Abstract] [Full-text]
62. Quandaries in prescribing an emergency action plan and self-injectable epinephrine for first-aid management of anaphylaxis in the community.
    J Allergy Clin Immunol, 115(3): 575-83. [Abstract] [Full-text]
63. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Cancer Res, 65(5): 1748-54. [Abstract] [Full-text]
64. Posttransplant symptomatic lymphocele treatment with percutaneous drainage and ethanol sclerosis: long-term follow-up.
    Clin Imaging, 29(2): 109-16. [Abstract] [Full-text]
65. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy.
    Int J Radiat Oncol Biol Phys, 61(4): 1216-26. [Abstract] [Full-text]
66. Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness.
    Int J Radiat Oncol Biol Phys, 61(4): 1136-42. [Abstract] [Full-text]
67. A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
    Int J Radiat Oncol Biol Phys, 61(4): 1117-22. [Abstract] [Full-text]
68. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium.
    Farmaco, 60(2): 171-7. [Abstract] [Full-text]
69. Rapid fluid infusion therapy decreases the plasma concentration of continuously infused propofol.
    Acta Anaesthesiol Scand, 49(3): 331-6. [Abstract] [Full-text]
70. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
    Br J Clin Pharmacol, 59(3): 325-34. [Abstract] [Full-text]
71. Successful treatment of an extensive verrucous carcinoma with topical 5-aminolevulinic acid-mediated photodynamic therapy.
    J Oral Pathol Med, 34(4): 253-6. [Abstract] [Full-text]
72. Pharmacokinetics and clinical effects of mono-L-aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces.
    Photodermatol Photoimmunol Photomed, 21(2): 72-8. [Abstract] [Full-text]
73. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century.
    Cancer, 103(6): 1103-13. [Abstract] [Full-text]
74. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
    Br J Cancer, 92(5): 832-7. [Abstract] [Full-text]
75. Incidence and prevalence of HIV encephalopathy in children with HIV infection receiving highly active anti-retroviral therapy (HAART).
    J Pediatr, 146(3): 402-7. [Abstract] [Full-text]
76. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
    Clin Cancer Res, 11(5): 1983-9. [Abstract] [Full-text]
77. A randomized, double-blinded, placebo-controlled phase II trial of recombinant human leukemia inhibitory factor (rhuLIF, emfilermin, AM424) to prevent chemotherapy-induced peripheral neuropathy.
    Clin Cancer Res, 11(5): 1890-8. [Abstract] [Full-text]
78. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer.
    Clin Cancer Res, 11(5): 1877-83. [Abstract] [Full-text]
79. Phase II evaluation of docetaxel-modulated capecitabine in previously treated patients with non-small cell lung cancer.
    Clin Cancer Res, 11(5): 1870-6. [Abstract] [Full-text]
80. Role of computerized physician order entry systems in facilitating medication errors.
    JAMA, 293(10): 1197-203. [Abstract] [Full-text]
81. Bortezomib in combination with dexamethasone for relapsed multiple myeloma.
    Leuk Res, 29(5): 587-90. [Abstract] [Full-text]
82. Medication use and prescribing considerations for elderly patients.
    Dent Clin North Am, 49(2): 411-27. [Abstract] [Full-text]
83. Evaluation of a drug-drug interaction alert structure through the retrospective analysis of statins-macrolides co-prescriptions.
    Basic Clin Pharmacol Toxicol, 96(4): 289-94. [Abstract] [Full-text]
84. Prediction of individual response to chemotherapy in patients with acute myeloid leukaemia using the chemosensitivity index Ci.
    Br J Haematol, 128(6): 783-91. [Abstract] [Full-text]
85. Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer.
    Br J Cancer, 92(5): 827-31. [Abstract] [Full-text]
86. Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes.
    Can J Physiol Pharmacol, 83(1): 98-103. [Abstract] [Full-text]
87. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution.
    J Vasc Interv Radiol, 16(3): 353-61. [Abstract] [Full-text]
88. Thrombolytic therapy for acute superior mesenteric artery occlusion.
    J Vasc Interv Radiol, 16(3): 317-29. [Abstract] [Full-text]
89. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.
    N Engl J Med, 352(10): 978-86. [Abstract] [Full-text]
90. Increased levels of serum osteoprotegerin in hypothyroid patients and its normalization with restoration of normal thyroid function.
    Eur J Endocrinol, 152(3): 347-53. [Abstract] [Full-text]
91. The role of antibiotic prophylaxis in clean incised hand injuries: a prospective randomized placebo controlled double blind trial.
    J Hand Surg [Br], 30(2): 162-7. [Abstract] [Full-text]
92. Approaches to improving the kinetics of adenovirus-delivered genes and gene products.
    Adv Drug Deliv Rev, 57(5): 781-802. [Abstract] [Full-text]
93. Physical methods for gene transfer: improving the kinetics of gene delivery into cells.
    Adv Drug Deliv Rev, 57(5): 733-53. [Abstract] [Full-text]
94. The hydrodynamics-based procedure for controlling the pharmacokinetics of gene medicines at whole body, organ and cellular levels.
    Adv Drug Deliv Rev, 57(5): 713-31. [Abstract] [Full-text]
95. Comparison of hormone levels in nipple aspirate fluid of pre- and postmenopausal women: effect of oral contraceptives and hormone replacement.
    J Clin Endocrinol Metab, 90(3): 1686-91. [Abstract] [Full-text]
96. Proniosomes as a drug carrier for transdermal delivery of ketorolac.
    Eur J Pharm Biopharm, 59(3): 485-90. [Abstract] [Full-text]
97. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
    Eur J Pharm Biopharm, 59(3): 431-8. [Abstract] [Full-text]
98. Albumin-protamine-oligonucleotide nanoparticles as a new antisense delivery system. Part 1: physicochemical characterization.
    Eur J Pharm Biopharm, 59(3): 419-29. [Abstract] [Full-text]
99. The rise and fall of menopausal hormone therapy.
    Annu Rev Public Health, 26: 115-40. [Abstract] [Full-text]
100. A history of thrombolytic therapy.
     J Endovasc Ther, 11: II128-133. [Abstract] [Full-text]
101. Advances in opioid therapy and formulations.
     Support Care Cancer, 13(3): 138-44. [Abstract] [Full-text]
102. Identifying target regions for vigilance improvement under hormone replacement therapy in postmenopausal syndrome patients by means of electroencephalographic tomography (LORETA).
     Psychopharmacology (Berl), 178(4): 389-99. [Abstract] [Full-text]
103. Mobile thrombi of the right heart in pulmonary embolism: delayed disappearance after thrombolytic treatment.
     Chest, 127(3): 1051-3. [Abstract] [Full-text]
104. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.
     Chest, 127(3): 909-15. [Abstract] [Full-text]
105. Pharmacotherapy for alcohol-related disorders: what clinicians should know.
     Harv Rev Psychiatry, 12(6): 351-66. [Abstract] [Full-text]
106. Evaluating direct-to-consumer marketing of race-based pharmacogenomics: a focus group study of public understandings of applied genomic medication.
     J Health Commun, 9(6): 541-59. [Abstract] [Full-text]
107. Is the information "fair and balanced" in direct-to-consumer prescription drug websites?
     J Health Commun, 9(6): 529-40. [Abstract] [Full-text]
108. A content analysis of direct-to-consumer television prescription drug advertisements.
     J Health Commun, 9(6): 515-28. [Abstract] [Full-text]
109. Direct-to-consumer advertising and its utility in health care decision making: a consumer perspective.
     J Health Commun, 9(6): 499-513. [Abstract] [Full-text]
110. Direct-to-consumer drug advertisements on network television: an exploration of quantity, frequency, and placement.
     J Health Commun, 9(6): 491-7. [Abstract] [Full-text]
111. Pharmaceutical insurance and the demand for prescription pharmaceuticals in Västerbotten, Sweden.
     Scand J Public Health, 33(1): 50-6. [Abstract] [Full-text]
112. Outcome for patients with metastatic (M2-3) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy.
     Eur J Cancer, 41(5): 727-34. [Abstract] [Full-text]
113. Effects of tamoxifen and octreotide LAR on the IGF-system compared with tamoxifen monotherapy.
     Eur J Cancer, 41(5): 694-701. [Abstract] [Full-text]
114. Evaluation of transportan 10 in PEI mediated plasmid delivery assay.
     J Control Release, 103(2): 511-23. [Abstract] [Full-text]
115. Influence of micro-environmental pH on the gel layer behavior and release of a basic drug from various hydrophilic matrices.
     J Control Release, 103(2): 499-510. [Abstract] [Full-text]
116. Influence of serum protein on polycarbonate-based copolymer micelles as a delivery system for a hydrophobic anti-cancer agent.
     J Control Release, 103(2): 481-97. [Abstract] [Full-text]
117. Developments in the rat adjuvant arthritis model and its use in therapeutic evaluation of novel non-invasive treatment by SOD in Transfersomes.
     J Control Release, 103(2): 419-34. [Abstract] [Full-text]
118. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis.
     J Control Release, 103(2): 381-92. [Abstract] [Full-text]
119. Thermosensitive and biodegradable polymeric micelles for paclitaxel delivery.
     J Control Release, 103(2): 341-53. [Abstract] [Full-text]
120. The vagina as a route for systemic drug delivery.
     J Control Release, 103(2): 301-13. [Abstract] [Full-text]
121. Prevalence and correlates of potentially inappropriate prescribing among ambulatory older patients in the year 2001: comparison of three explicit criteria.
     Clin Ther, 27(1): 88-99. [Abstract] [Full-text]
122. Illuminating drug discovery with biological pathways.
     FEBS Lett, 579(8): 1872-7. [Abstract] [Full-text]
123. PEG-appended beta-(1-->3)-D-glucan schizophyllan to deliver antisense-oligonucleotides with avoiding lysosomal degradation.
     Biomaterials, 26(23): 4866-73. [Abstract] [Full-text]
124. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate.
     Biomaterials, 26(23): 4856-65. [Abstract] [Full-text]
125. Chemotherapy for retinoblastoma.
     Ophthalmol Clin North Am, 18(1): 55-63, viii. [Abstract] [Full-text]
126. Direct in vivo protein transduction into a specific restricted brain area in rats.
     Neurosci Lett, 378(1): 18-21. [Abstract] [Full-text]
127. Changes in attitudes, knowledge and hormone replacement therapy use: a comparative study in two random samples with 6-year interval.
     Acta Obstet Gynecol Scand, 84(4): 395-401. [Abstract] [Full-text]
128. Prospective randomized comparison of single-dose versus 1-day cefazolin for prophylaxis in gynecologic surgery.
     Acta Obstet Gynecol Scand, 84(4): 384-9. [Abstract] [Full-text]
129. Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire.
     Clin Exp Immunol, 140(1): 138-48. [Abstract] [Full-text]
130. Synthesis of novel folic acid-functionalized biocompatible block copolymers by atom transfer radical polymerization for gene delivery and encapsulation of hydrophobic drugs.
     Biomacromolecules, 6(2): 1085-96. [Abstract] [Full-text]
131. Formation of core/shell nanoparticles with a lipid core and their application as a drug delivery system.
     Biomacromolecules, 6(2): 1062-7. [Abstract] [Full-text]
132. Novel, fluorescent, magnetic, polysaccharide-based microsphere for orientation, tracing, and anticoagulation: preparation and characterization.
     Biomacromolecules, 6(2): 1041-7. [Abstract] [Full-text]
133. Synthesis of well-defined amphiphilic block copolymers having phospholipid polymer sequences as a novel biocompatible polymer micelle reagent.
     Biomacromolecules, 6(2): 663-70. [Abstract] [Full-text]
134. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart.
     Nat Biotechnol, 23(3): 321-8. [Abstract] [Full-text]
135. Short communication: the efficacy of fixed dose rate infusion of gemcitabine combined with IFN-alpha2a in patients with advanced refractory renal cell carcinoma.
     J Interferon Cytokine Res, 25(3): 165-8. [Abstract] [Full-text]
136. Hormone therapy, lipoprotein subclasses, and coronary calcification: the Healthy Women Study.
     Arch Intern Med, 165(5): 510-5. [Abstract] [Full-text]
137. Is thrombolytic therapy associated with increased mortality? Meta-analysis of randomized controlled trials.
     Arch Neurol, 62(3): 362-6. [Abstract] [Full-text]
138. Three cases of large retinal capillary hemangiomas treated with verteporfin and photodynamic therapy.
     Arch Ophthalmol, 123(3): 328-32. [Abstract] [Full-text]
139. Controlled trials to improve antibiotic utilization: a systematic review of experience, 1984-2004.
     Pharmacotherapy, 25(2): 289-98. [Abstract] [Full-text]
140. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
     Pharmacotherapy, 25(1): 35-41. [Abstract] [Full-text]
141. A spike in fatal medication errors at the beginning of each month.
     Pharmacotherapy, 25(1): 1-9. [Abstract] [Full-text]
142. The effects of adjuvant chemotherapy on cognition in women with breast cancer--preliminary results of an observational longitudinal study.
     Breast, 14(2): 142-50. [Abstract] [Full-text]
143. First-line chemotherapy with docetaxel and cisplatin in metastatic breast cancer.
     Breast, 14(2): 136-41. [Abstract] [Full-text]
144. Current trends in thrombolysis: implications for diagnostic and interventional radiology.
     Clin Radiol, 60(4): 413-24. [Abstract] [Full-text]
145. Verteporfin photodynamic therapy for the treatment of persistent subfoveal choroidal neovascularization after external beam radiotherapy: one-year results.
     Am J Ophthalmol, 139(3): 561-2. [Abstract] [Full-text]
146. Experimental study of an automated system for the delivery of eyedrops using a microinfusion pump.
     Am J Ophthalmol, 139(3): 547-9. [Abstract] [Full-text]
147. The safety profile of long-term, high-dose intraocular corticosteroid delivery.
     Am J Ophthalmol, 139(3): 421-8. [Abstract] [Full-text]
148. Pharmacokinetics of combined doxorubicin and paclitaxel in mice.
     Cancer Lett, 220(2): 161-9. [Abstract] [Full-text]
149. Alkylated derivatives of poly(ethylacrylic acid) can be inserted into preformed liposomes and trigger pH-dependent intracellular delivery of liposomal contents.
     Mol Membr Biol, 21(6): 385-93. [Abstract] [Full-text]
150. Optimizing the treatment of metastatic breast cancer.
     Breast Cancer Res Treat, 89: S9-S15. [Abstract] [Full-text]
151. The future of breast cancer: the role of prognostic factors.
     Breast Cancer Res Treat, 89: S17-26. [Abstract] [Full-text]
152. Evolving treatment approaches for early breast cancer.
     Breast Cancer Res Treat, 89: S1-7. [Abstract] [Full-text]
153. Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells.
     Breast Cancer Res Treat, 90(1): 25-31. [Abstract] [Full-text]
154. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy.
     J Natl Cancer Inst, 97(6): 425-32. [Abstract] [Full-text]
155. Potentially inappropriate medication use among elderly home care patients in Europe.
     JAMA, 293(11): 1348-58. [Abstract] [Full-text]
156. Bovine BMP osteoinductive potential enhanced by functionalized dextran-derived hydrogels.
     Biomaterials, 26(24): 5085-92. [Abstract] [Full-text]
157. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly(N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly(D,L-lactide-co-glycolide) with varying compositions.
     Biomaterials, 26(24): 5064-74. [Abstract] [Full-text]
158. Directed cell migration via chemoattractants released from degradable microspheres.
     Biomaterials, 26(24): 5048-63. [Abstract] [Full-text]
159. Pyrazolyl derivatives as bifunctional chelators for labeling tumor-seeking peptides with the fac-[M(CO)3]+ moiety (M = 99mTc, Re): synthesis, characterization, and biological behavior.
     Bioconjug Chem, 16(2): 438-49. [Abstract] [Full-text]
160. Synthesis and evaluation of a star amphiphilic block copolymer from poly(epsilon-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier.
     Bioconjug Chem, 16(2): 397-405. [Abstract] [Full-text]
161. Cytotoxic activity of a tumor protease-activated pore-forming toxin.
     Bioconjug Chem, 16(2): 369-76. [Abstract] [Full-text]
162. pH-Responsive copolymer assemblies for controlled release of doxorubicin.
     Bioconjug Chem, 16(2): 361-8. [Abstract] [Full-text]
163. Synthesis, cellular transport, and activity of polyamidoamine dendrimer-methylprednisolone conjugates.
     Bioconjug Chem, 16(2): 330-7. [Abstract] [Full-text]
164. Supramolecular gene delivery vectors showing enhanced transgene expression and good biocompatibility.
     Bioconjug Chem, 16(2): 322-9. [Abstract] [Full-text]
165. Infusional 5-fluorouracil and mitomycin C: an effective regimen in the treatment of advanced gastric cancer.
     Onkologie, 28(3): 128-32. [Abstract] [Full-text]
166. Postmenopausal hormone replacement therapy increases plasmatic thromboxane beta 2.
     Int J Cardiol, 99(3): 449-54. [Abstract] [Full-text]
167. Short-term combinational therapy of low-dose estrogen with selective serotonin re-uptake inhibitor (fluvoxamine) for oophorectomized women with hot flashes and depressive tendencies.
     J Obstet Gynaecol Res, 31(2): 107-14. [Abstract] [Full-text]
168. Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck.
     Head Neck, 27(4): 311-9. [Abstract] [Full-text]
169. Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women.
     J Appl Physiol, 98(4): 1341-8. [Abstract] [Full-text]
170. The effect of hormone replacement therapy and simvastatin on plasma homocysteine.
     J Womens Health (Larchmt), 14(2): 154-8. [Abstract] [Full-text]
171. Insulin sensitivity in women with coronary heart disease during hormone replacement therapy.
     J Womens Health (Larchmt), 14(2): 137-45. [Abstract] [Full-text]
172. Use of herbal medicine in primary care patients with mood and anxiety disorders.
     Psychosomatics, 46(2): 117-22. [Abstract] [Full-text]
173. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
     J Clin Oncol, 23(9): 2004-11. [Abstract] [Full-text]
174. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications.
     J Clin Oncol, 23(9): 1951-61. [Abstract] [Full-text]
175. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer: updated results of a prospective randomized trial.
     J Clin Oncol, 23(9): 1934-40. [Abstract] [Full-text]
176. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer.
     J Clin Oncol, 23(9): 1819-25. [Abstract] [Full-text]
177. Standard variables fail to identify patients who will not respond to fluid resuscitation following thermal injury: brief report.
     Burns, 31(3): 358-65. [Abstract] [Full-text]
178. Prospective, randomized, multicentric, open, comparative study on the efficacy of a prophylactic single dose of 500 mg levofloxacin versus 1920 mg trimethoprim/sulfamethoxazole versus a control group in patients undergoing TUR of the prostate.
     Eur Urol, 47(4): 549-56. [Abstract] [Full-text]
179. Support ellagic acid therapy in patients with hormone refractory prostate cancer (HRPC) on standard chemotherapy using vinorelbine and estramustine phosphate.
     Eur Urol, 47(4): 449-54; discussion 454-5. [Abstract] [Full-text]
180. Photodynamic therapy using a novel photosensitizer, ATX-S10(Na): comparative effect with 5-aminolevulinic acid on squamous cell carcinoma cell line, SCC15, ultraviolet B-induced skin tumor, and phorbol ester-induced hyperproliferative skin.
     Arch Dermatol Res, 296(10): 496-502. [Abstract] [Full-text]
181. Long-term survival and interruption of HAART in HIV-related pulmonary hypertension.
     Eur J Clin Microbiol Infect Dis, 24(2): 153-5. [Abstract] [Full-text]
182. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors.
     J Clin Oncol, 23(9): 1875-84. [Abstract] [Full-text]
183. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
     J Clin Oncol, 23(9): 1984-92. [Abstract] [Full-text]
184. Origin and uses of primum non nocere--above all, do no harm!
     J Clin Pharmacol, 45(4): 371-7. [Abstract] [Full-text]
185. Alteplase and ischaemic stroke: have new reviews of old data helped?
     Lancet Neurol, 4(4): 249-53. [Abstract] [Full-text]
186. Pharmacokinetics and biodistribution of RGD-targeted doxorubicin-loaded nanoparticles in tumor-bearing mice.
     Int J Pharm, 293(1): 281-90. [Abstract] [Full-text]
187. Poly(ethylene oxide)-modified poly(epsilon-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer.
     Int J Pharm, 293(1): 261-70. [Abstract] [Full-text]
188. In vitro drug release mechanism and drug loading studies of cubic phase gels.
     Int J Pharm, 293(1): 241-50. [Abstract] [Full-text]
189. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies.
     Int J Pharm, 293(1): 213-23. [Abstract] [Full-text]
190. In vivo evaluation of tablets and capsules containing spray-dried o/w-emulsions for oral delivery of poorly soluble drugs.
     Int J Pharm, 293(1): 203-11. [Abstract] [Full-text]
191. Ketorolac amide prodrugs for transdermal delivery: stability and in vitro rat skin permeation studies.
     Int J Pharm, 293(1): 193-202. [Abstract] [Full-text]
192. Improvement of absorption enhancing effects of n-dodecyl-beta-D-maltopyranoside by its colon-specific delivery using chitosan capsules.
     Int J Pharm, 293(1): 127-35. [Abstract] [Full-text]
193. Diethyl methyl chitosan as an intestinal paracellular enhancer: ex vivo and in vivo studies.
     Int J Pharm, 293(1): 83-9. [Abstract] [Full-text]
194. Non-invasive vaccine delivery in transfersomes, niosomes and liposomes: a comparative study.
     Int J Pharm, 293(1): 73-82. [Abstract] [Full-text]
195. Usefulness of coadministration of bucolome in warfarin therapy: pharmacokinetic and pharmacodynamic analysis using outpatient prescriptions.
     Int J Pharm, 293(1): 43-9. [Abstract] [Full-text]
196. Release characterization of dimenhydrinate from an eroding and swelling matrix: selection of appropriate dissolution apparatus.
     Int J Pharm, 293(1): 35-42. [Abstract] [Full-text]
197. Evaluation of a water-soluble bioadhesive patch for photodynamic therapy of vulval lesions.
     Int J Pharm, 293(1): 11-23. [Abstract] [Full-text]
198. Phase II trial of oral vinorelbine in combination with cisplatin followed by consolidation therapy with oral vinorelbine in advanced NSCLC.
     Lung Cancer, 48(1): 129-35. [Abstract] [Full-text]
199. Phase I study of combination chemotherapy with gemcitabine and irinotecan for non-small cell lung cancer.
     Lung Cancer, 48(1): 115-9. [Abstract] [Full-text]
200. Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
     Lung Cancer, 48(1): 93-102. [Abstract] [Full-text]
201. Prevention of medication errors.
     Clin Perinatol, 32(1): 107-23, vii. [Abstract] [Full-text]
202. Cardiovascular risk at age 53 years in relation to the menopause transition and use of hormone replacement therapy: a prospective British birth cohort study.
     BJOG, 112(4): 476-85. [Abstract] [Full-text]
203. LightCycler-based quantitative real-time PCR monitoring of patients with follicular lymphoma receiving rituximab in combination with conventional or high-dose cytotoxic chemotherapy.
     Eur J Haematol, 74(4): 282-92. [Abstract] [Full-text]
204. Mini-ICE effectively mobilises peripheral blood stem cells after fludarabine-based regimens in acute myeloid leukaemia.
     Eur J Haematol, 74(4): 277-81. [Abstract] [Full-text]
205. Thin cylindrical diffusers in multimode Ge-doped silica fibers.
     Lasers Surg Med, 36(3): 245-51. [Abstract] [Full-text]
206. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
     Osteoporos Int, 16(4): 372-9. [Abstract] [Full-text]
207. Is mechanical bowel preparation mandatory for elective colon surgery? A prospective randomized study.
     Arch Surg, 140(3): 285-8. [Abstract] [Full-text]
208. 19-Nor-1,25(OH)2D2 (a novel, noncalcemic vitamin D analogue), combined with arsenic trioxide, has potent antitumor activity against myeloid leukemia.
     Cancer Res, 65(6): 2488-97. [Abstract] [Full-text]
209. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
     Cancer Res, 65(6): 2422-32. [Abstract] [Full-text]
210. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance.
     Cancer Res, 65(6): 2397-405. [Abstract] [Full-text]
211. Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
     Cancer Res, 65(6): 2364-72. [Abstract] [Full-text]
212. Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro.
     Cancer Res, 65(6): 2344-52. [Abstract] [Full-text]
213. Perioperative fluid management and clinical outcomes in adults.
     Anesth Analg, 100(4): 1093-106. [Abstract] [Full-text]
214. The impact of carrier flow rate and infusion set dead-volume on the dynamics of intravenous drug delivery.
     Anesth Analg, 100(4): 1048-55. [Abstract] [Full-text]
215. Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy.
     Bioorg Med Chem, 13(8): 2799-808. [Abstract] [Full-text]
216. Targeting survival signaling in heart failure.
     Curr Opin Pharmacol, 5(2): 165-70. [Abstract] [Full-text]
217. Intranasal 17beta-estradiol treatment and Vitamin B12, folate and homocysteine in menopause.
     Maturitas, 50(4): 353-8. [Abstract] [Full-text]
218. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
     Maturitas, 50(4): 344-52. [Abstract] [Full-text]
219. Serum androgen levels and insulin resistance in postmenopausal women: association with hormone therapy, tibolone and raloxifene.
     Maturitas, 50(4): 321-30. [Abstract] [Full-text]
220. Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.
     Maturitas, 50(4): 312-20. [Abstract] [Full-text]
221. Different effect of hormone replacement therapy, DHEAS and tibolone on endothelial function in postmenopausal women with increased cardiovascular risk.
     Maturitas, 50(4): 305-11. [Abstract] [Full-text]
222. Long-term treatment with vaginal estradiol tablets--an impact on uterine artery blood flow.
     Maturitas, 50(4): 300-4. [Abstract] [Full-text]
223. Effects of transdermal estrogen replacement therapy on plasma levels of nitric oxide and plasma lipids in postmenopausal women.
     Maturitas, 50(4): 289-93. [Abstract] [Full-text]
224. Early impact of hormone replacement therapy on vascular hemodynamics detected via ocular colour Doppler analysis.
     Maturitas, 50(4): 282-8. [Abstract] [Full-text]
225. Effects in post-menopausal women of transdermal estrogen associated with progestin upon the removal from the plasma of a microemulsion that resembles low-density lipoprotein (LDL).
     Maturitas, 50(4): 275-81. [Abstract] [Full-text]
226. Acute administration of 17beta-estradiol improves endothelium-dependent vasodilation in postmenopausal women.
     Maturitas, 50(4): 266-74. [Abstract] [Full-text]
227. Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Open prospective study with Doppler ultrasonography in internal carotid artery.
     Maturitas, 50(4): 259-65. [Abstract] [Full-text]
228. Differential estrogen signaling in endothelial cells upon pulsed or continuous administration.
     Maturitas, 50(4): 247-58. [Abstract] [Full-text]
229. Value of C-reactive protein levels and IL-6 in predicting events levels in women at increased cardiovascular risk.
     Maturitas, 50(4): 239-46. [Abstract] [Full-text]
230. Estradiol induced inhibition of 11beta-hydroxysteroid dehydrogenase 1: an explanation for the postmenopausal hormone replacement therapy effects.
     Med Hypotheses, 64(5): 989-91. [Abstract] [Full-text]
231. HER1/EGFR-targeted agents: predicting the future for patients with unpredictable outcomes to therapy.
     Ann Oncol, 16(4): 538-48. [Abstract] [Full-text]
232. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
     Ann Oncol, 16(4): 602-10. [Abstract] [Full-text]
233. mTOR-targeted therapy of cancer with rapamycin derivatives.
     Ann Oncol, 16(4): 525-37. [Abstract] [Full-text]
234. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
     Ann Oncol, 16(4): 549-57. [Abstract] [Full-text]
235. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
     Blood, 105(7): 2677-84. [Abstract] [Full-text]
236. Maintenance of ovarian function and risk of premature menopause related to cancer treatment.
     J Natl Cancer Inst Monogr. [Abstract] [Full-text]
237. Spermatogenesis after cancer treatment: damage and recovery.
     J Natl Cancer Inst Monogr. [Abstract] [Full-text]
238. Use of intrapleural streptokinase in experimental minimal clotted hemothorax.
     Eur J Cardiothorac Surg, 27(4): 667-70. [Abstract] [Full-text]
239. Catamenial pneumothorax: optimal hormonal and surgical management.
     Eur J Cardiothorac Surg, 27(4): 662-6. [Abstract] [Full-text]
240. Preparation and evaluation of release characteristics of 3TabGum, a novel chewing device.
     Eur J Pharm Sci, 24(5): 487-93. [Abstract] [Full-text]
241. Effect of self-microemulsifying drug delivery systems containing Labrasol on tight junctions in Caco-2 cells.
     Eur J Pharm Sci, 24(5): 477-86. [Abstract] [Full-text]
242. Pegylated nanoparticles based on poly(methyl vinyl ether-co-maleic anhydride): preparation and evaluation of their bioadhesive properties.
     Eur J Pharm Sci, 24(5): 411-9. [Abstract] [Full-text]
243. Use of veterinary antiprotozoal products in the UK, 1998-2002.
     Int J Antimicrob Agents, 25(4): 279-81. [Abstract] [Full-text]
244. Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer.
     Br J Cancer, 92(6): 1013-8. [Abstract] [Full-text]
245. Phase I/II study of oral etoposide plus GM-CSF as second-line chemotherapy in platinum-pretreated patients with advanced ovarian cancer.
     Br J Cancer, 92(6): 1019-25. [Abstract] [Full-text]
246. Phase I study of temozolomide plus paclitaxel in patients with advanced malignant melanoma and associated in vitro investigations.
     Br J Cancer, 92(6): 1006-12. [Abstract] [Full-text]
247. High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia.
     Bone Marrow Transplant, 35(7): 653-61. [Abstract] [Full-text]
248. Modelling human granulopoiesis under poly-chemotherapy with G-CSF support.
     J Math Biol, 50(4): 397-439. [Abstract] [Full-text]
249. Antibiotic prophylaxis and third molar surgery.
     Br Dent J, 198(6): 327-30. [Abstract] [Full-text]
250. Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
     Clin Cancer Res, 11(6): 2398-407. [Abstract] [Full-text]
251. Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy.
     Clin Cancer Res, 11(6): 2149-55. [Abstract] [Full-text]
252. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
     N Engl J Med, 352(12): 1197-205. [Abstract] [Full-text]
253. Medicine taking decisions: schizophrenia in comparison to asthma and epilepsy.
     J Psychiatr Ment Health Nurs, 12(2): 163-72. [Abstract] [Full-text]
254. Insulin pump use in young adolescents with type 1 diabetes: a descriptive study.
     Pediatr Diabetes, 6(1): 22-31. [Abstract] [Full-text]
255. Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective.
     Pediatr Diabetes, 6(1): 17-21. [Abstract] [Full-text]
256. Pilot study of topical delivery of methotrexate by electroporation.
     Br J Dermatol, 152(3): 524-30. [Abstract] [Full-text]
257. Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine.
     Diabet Med, 22(4): 382-6. [Abstract] [Full-text]
258. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation.
     N Engl J Med, 352(12): 1179-89. [Abstract] [Full-text]
259. The clinical significance of malignant pleural effusions in patients with optimally debulked ovarian carcinoma.
     Cancer, 103(7): 1397-401. [Abstract] [Full-text]
260. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors.
     Cancer, 103(7): 1402-7. [Abstract] [Full-text]
261. Sequential topotecan and oral etoposide in recurrent ovarian carcinoma pretreated with platinum-taxane. Results from a multicenter phase I/II study.
     Cancer, 103(7): 1388-96. [Abstract] [Full-text]
262. Macular function after PDT in myopic maculopathy: psychophysical and electrophysiological evaluation.
     Invest Ophthalmol Vis Sci, 46(4): 1453-62. [Abstract] [Full-text]
263. Neoadjuvant combined chemotherapy followed by external whole pelvic irradiation in two cases of primary extranodal non-Hodgkin's lymphoma of the uterine cervix.
     Gynecol Oncol, 97(1): 285-7. [Abstract] [Full-text]
264. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin.
     Gynecol Oncol, 97(1): 228-33. [Abstract] [Full-text]
265. A case of pure-type ovarian squamous cell carcinoma for which combination chemotherapy consisting of paclitaxel and carboplatin was not effective.
     Gynecol Oncol, 97(1): 223-7. [Abstract] [Full-text]
266. Primary stage I-IIE non-Hodgkin's lymphoma of uterine cervix and upper vagina: evidence for a conservative approach in a study on three patients.
     Gynecol Oncol, 97(1): 214-8. [Abstract] [Full-text]
267. Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
     Gynecol Oncol, 97(1): 200-5. [Abstract] [Full-text]
268. Survival benefit for patients with advanced-stage transitional cell carcinomas vs. other subtypes of ovarian carcinoma after chemotherapy with platinum and paclitaxel.
     Gynecol Oncol, 97(1): 195-9. [Abstract] [Full-text]
269. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma.
     Gynecol Oncol, 97(1): 171-7. [Abstract] [Full-text]
270. A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma.
     Gynecol Oncol, 97(1): 60-7. [Abstract] [Full-text]
271. Haemophagocytic lymphohistiocytosis in Malaysian children.
     J Paediatr Child Health, 41(3): 136-9. [Abstract] [Full-text]
272. Antibiotic prophylaxis of early onset pneumonia in critically ill comatose patients. A randomized study.
     Intensive Care Med, 31(4): 510-6. [Abstract] [Full-text]
273. Pulse pressure variations to predict fluid responsiveness: influence of tidal volume.
     Intensive Care Med, 31(4): 517-23. [Abstract] [Full-text]
274. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
     BMJ, 330(7493): 695. [Abstract] [Full-text]
275. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
     J Antimicrob Chemother, 55(4): 417-9. [Abstract] [Full-text]
276. Partial immune reconstitution following highly active antiretroviral therapy: can adjuvant interleukin-2 fill the gap?
     J Antimicrob Chemother, 55(4): 401-9. [Abstract] [Full-text]
277. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients.
     J Antimicrob Chemother, 55(4): 546-9. [Abstract] [Full-text]
278. The latent HIV-1 reservoir in patients undergoing HAART: an archive of pre-HAART drug resistance.
     J Antimicrob Chemother, 55(4): 410-2. [Abstract] [Full-text]
279. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven.
     J Antimicrob Chemother, 55(4): 413-6. [Abstract] [Full-text]
280. Neural network modeling and control of type 1 diabetes mellitus.
     Bioprocess Biosyst Eng, 27(2): 75-9. [Abstract] [Full-text]
281. Pilot phase II study of gemcitabine and vinorelbine in patients with recurrent or refractory small cell lung cancer.
     Lung, 183(1): 43-52. [Abstract] [Full-text]
282. Increased hemoglobin levels and improved quality-of-life assessments during epoetin alfa treatment in anemic cancer patients: results of a prospective, multicenter German trial.
     Oncologist, 10(3): 225-37. [Abstract] [Full-text]
283. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
     Oncologist, 10(3): 205-14. [Abstract] [Full-text]
284. Effect of albumin on the photodynamic inactivation of microorganisms by a cationic porphyrin.
     J Photochem Photobiol B, 79(1): 51-7. [Abstract] [Full-text]
285. Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl ch